on GENOWAY (EPA:ALGEN)
GenOway signs a strategic agreement with Taconic Biosciences
genOway, a European player in preclinical solutions, announces an exclusive partnership with the American company Taconic Biosciences for the distribution of its humanized models in the United States. This country represents the world's largest market in the preclinical model sector and generates more than 50% of genOway's sales.
The agreement is expected to accelerate genOway's commercial development thanks to the complementary nature of their offerings and customers. It opens up the potential to double genOway's business in North America. Taconic Biosciences, with its extensive sales network, promises greater visibility and increased sales opportunities for genOway.
The expected synergies aim to increase profitability while maintaining the quality of preclinical offerings, which should quickly have a positive impact on the financial results of the French group.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENOWAY news